Xavier Montalbán

Xavier Montalbán

UNVERIFIED PROFILE

Are you Xavier Montalbán?   Register this Author

Register author
Xavier Montalbán

Xavier Montalbán

Publications by authors named "Xavier Montalbán"

Are you Xavier Montalbán?   Register this Author

100Publications

3397Reads

48Profile Views

Cerebrospinal fluid mitochondrial DNA levels in patients with multiple sclerosis.

Mult Scler 2019 Oct 9;25(11):1535-1538. Epub 2018 Jul 9.

Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1352458518786055DOI Listing
October 2019

Brain regional volume estimations with NeuroQuant and FIRST: a study in patients with a clinically isolated syndrome.

Neuroradiology 2019 Jun 5;61(6):667-674. Epub 2019 Mar 5.

Neuroradiology Section, Department of Radiology, Vall d'Hebron University Hospital and Research Institute (VHIR), Autonomous University, Psg. Vall d'Hebron 119-129, 08035, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00234-019-02191-3DOI Listing
June 2019

Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.

N Engl J Med 2019 06 10;380(25):2406-2417. Epub 2019 May 10.

From Vall d'Hebron University Hospital, Barcelona (X.M.); St. Michael's Hospital, University of Toronto, Toronto (X.M.), and Montreal Neurological Institute and NeuroRx Research, Montreal (D.L.A.) - both in Canada; the Institute of Neuropathology and the Department of Neurology, University Medical Center, Göttingen, Germany (M.S.W.); the Department of Neurology, Acibadem City Clinic Tokuda Hospital, Sofia, Bulgaria (I.S.); the Department of Histology and Embryology, Poznan University of Medical Science, Poznan, Poland (K.P.-S.); the Global Clinical Development Center, EMD Serono Research and Development Institute, Billerica, MA (J.W., E.M., F.D., S.S.); and McGovern Medical School, University of Texas Health Science Center at Houston, Houston (J.S.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1901981DOI Listing
June 2019

A pharmacogenetic study implicates in the response to Interferon-β in multiple sclerosis.

Mult Scler 2019 Jun 21:1352458519851428. Epub 2019 Jun 21.

Laboratory of Human Genetics of Neurological Disorders, Institute of Experimental Neurology (INSPE), IRCCS San Raffaele Scientific Institute, Milan, Italy/Department of Biomedical Sciences for Health, University of Milan, Milan, Italy/Department of Neurology, IRCCS Policlinico San Donato, San Donato Milanese, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1352458519851428DOI Listing
June 2019

Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis.

J Neurol 2019 May 28;266(5):1182-1193. Epub 2019 Feb 28.

Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00415-019-09248-6
Publisher Site
http://dx.doi.org/10.1007/s00415-019-09248-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469695PMC
May 2019

Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis.

Nat Rev Neurol 2019 May;15(5):287-300

Division of Neurology, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-019-0170-8DOI Listing
May 2019

Oligoclonal bands do not represent dissemination in time in the 2017 revisions to the McDonald criteria.

Mult Scler 2019 May 16:1352458519846103. Epub 2019 May 16.

1 Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya, (Cemcat), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1352458519846103
Publisher Site
http://dx.doi.org/10.1177/1352458519846103DOI Listing
May 2019

Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials.

Mult Scler 2019 04 9;25(4):565-573. Epub 2018 Mar 9.

Department of Neurology, Klinikum rechts der Isar, Technische Universität München, München, Germany/German Competence Network Multiple Sclerosis (KKNMS), München, Germany/Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1352458518763089DOI Listing
April 2019

The Multiple Sclerosis Care Unit.

Mult Scler 2019 Apr 23;25(5):627-636. Epub 2018 Oct 23.

Department of Neurology and Institute of Experimental Neurology, Vita-Salute San Raffaele University, San Raffaele Hospital, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1352458518807082DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439947PMC
April 2019

Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis.

Mult Scler Relat Disord 2019 Apr 20;29:157-167. Epub 2018 Nov 20.

Merck KGaA, Frankfurter Str. 250, 64293 Darmstadt, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.msard.2018.11.021DOI Listing
April 2019

Expression of Bone Morphogenetic Proteins in Multiple Sclerosis Lesions.

Am J Pathol 2019 Mar 13;189(3):665-676. Epub 2018 Dec 13.

Neurology-Neuroimmunology Department, Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d'Hebron Research Institute (VHIR), Vall d'Hebron University Hospital, Barcelona, Spain; Autonomous University of Barcelona, Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajpath.2018.11.007DOI Listing
March 2019

Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis.

Neurology 2019 Mar 1;92(13):e1507-e1516. Epub 2019 Mar 1.

From the Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology (M.I.Z., S.O.-R., G.A., L.N., I.G., J.R., M.C., C.N., M.J.A., A.V.-J., J.C., B.R., L.M., P.M., J.S.-G., X.M., M.T.), and Unitat de RM, Servei de Radiologia (M.I.Z., A.R., L.N., R.M., C.A., X.M.), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona; Unitat d'Estadística i Bioinformàtica (UEB) (M.I.Z., S.P.-H., L.N., X.M.), Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain; Servicio de Neurología (M.I.Z., L.N., X.M.), Instituto Neurológico de Colombia, Medellín, Colombia; Raul Carrea Institute for Neurological Research (L.N., X.M.), FLENI, Buenos Aires, Argentina; and Division of Neurology (X.M.), St. Michael's Hospital, University of Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000007178DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6453769PMC
March 2019

Does attendance at the ECTRIMS congress impact on therapeutic decisions in multiple sclerosis care?

Mult Scler J Exp Transl Clin 2019 Jan-Mar;5(1):2055217319835226. Epub 2019 Mar 18.

Department of Medicine, St. Michael's Hospital, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2055217319835226DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6423673PMC
March 2019

Simultaneous CMV and infection following alemtuzumab treatment for multiple sclerosis.

Neurology 2019 Feb 26;92(6):296-298. Epub 2018 Dec 26.

From the Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia (Cemcat) (A.P., L.M., J.C., P.M., A.V.-J., G.A., B.R.-A., J.S.-G., J.R., M.C., I.G., M.T., X.M.), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; Department of Internal Medicine (C.P.B.R.) and Center of Biomedical Research in Network on Neurodegenerative Diseases (CIBERNED) (C.P.B.R.), Sant Joan d'Alacant University Hospital, Alicante, Spain; Department of Neurology (A.P.), Hospital Italiano, Buenos Aires, Argentina; Department of Infectious Diseases (C.P.B.R., A.A.P., I.R.C.) and Microbiology Department (M.L.), Vall d'Hebron University Hospital, Barcelona, Spain; and Division of Neurology (X.M.), University of Toronto, St Michael's Hospital, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000006801DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382059PMC
February 2019

Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge.

Neurology 2019 Jan 26;92(4):180-192. Epub 2018 Dec 26.

From the Department of Neurosciences (C.G., L.P.), San Camillo-Forlanini Hospital, Rome, Italy; Centre d'Esclerosi Multiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology (M.T., J.R., J.S.-G., X.M.), and Magnetic Resonance Unit, Department of Radiology (A.R.), Hospital Universitari Vall d'Hebron, Universitat Autonoma de Barcelona, Spain; Biostatistics Unit (M.P.S.), Department of Health Sciences, University of Genoa; Neuroimaging Research Unit (M.F., M.A.R.), Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy; Nuffield Department of Clinical Neurosciences (J.P.), West Wing, John Radcliffe Hospital, Oxford; Institutes of Neurology & Healthcare Engineering (O.C., F.B.), University College London (O.C.), UK; Amsterdam Neuroscience and Department of Radiology and Nuclear Medicine (F.B., H.V.), VU University Medical Center, Amsterdam, the Netherlands; Department of Neurology (J.L.F.), Rigshospitalet Glostrup and University of Copenhagen, Denmark; Neuroradiological Academic Unit (T.A.Y.), Institute of Neurology, London, UK; Department of Neurology (C.E.), Medical University of Graz, Austria; Neurologic Clinic and Policlinic, Department of Medicine (L.K.), Clinical Research, Biomedicine and Biomedical Engineering, University Hospital Basel, University of Basel, Switzerland; Department of Neurology and Psychiatry (C.P.), Sapienza University, Rome; and Neurology and Neurometabolic Unit, Department of Neurological and Behavioral Sciences (N.D.S.), University of Siena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000006810DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345120PMC
January 2019

Multiple sclerosis: clinical aspects.

Curr Opin Neurol 2018 12;31(6):752-759

Division of Neurology, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00019052-900000000-9908
Publisher Site
http://dx.doi.org/10.1097/WCO.0000000000000622DOI Listing
December 2018

NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients.

Mult Scler 2018 10 9;24(11):1507-1510. Epub 2017 Nov 9.

Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat) and Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1352458517739137DOI Listing
October 2018

Circulating EZH2-positive T cells are decreased in multiple sclerosis patients.

J Neuroinflammation 2018 Oct 26;15(1):296. Epub 2018 Oct 26.

Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12974-018-1336-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6202809PMC
October 2018

Severe hypertriglyceridemia associated with teriflunomide in a patient with multiple sclerosis: A case report.

Mult Scler 2018 09 23;24(10):1383-1385. Epub 2018 Feb 23.

Servei de Neurología-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1352458518761185DOI Listing
September 2018

Cladribine tablets added to IFN-β in active relapsing MS: The ONWARD study.

Neurol Neuroimmunol Neuroinflamm 2018 Sep 11;5(5):e477. Epub 2018 Jul 11.

Department of Neurology-Neuroimmunology (X.M.), Multiple Sclerosis Center of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain; Department of Neurology (X.M.), St. Michael's Hospital, University of Toronto, Ontario, Canada; Division of Clinical Neuroimmunology (T.P.L.), Jefferson University, Comprehensive MS Center, Philadelphia, PA; Department of Neurology (B.A.C.), Feinberg School of Medicine, Northwestern University, Chicago, IL; Department of Neurology (H.M.), Vanderbilt University Medical Center, Nashville, TN; inScience Communications (J.C.), Springer Healthcare, Chester, United Kingdom; Research and Development Global BioStatistics (C.H.), Merck KGaA, Darmstadt, Germany; and Global Clinical Development Center (F.D.), EMD Serono Inc., Billerica, MA.

View Article

Download full-text PDF

Source
http://nn.neurology.org/lookup/doi/10.1212/NXI.0000000000000
Publisher Site
http://dx.doi.org/10.1212/NXI.0000000000000477DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047834PMC
September 2018

Myasthenia gravis following alemtuzumab therapy for multiple sclerosis.

Neurology 2018 09 24;91(13):622-624. Epub 2018 Aug 24.

From the Servei de Neurologia/Neuroimmunologia, Multiple Sclerosis Centre of Catalonia (CEM-Cat) (L.M., J.S.-G., X.M., M.T.), Servei de Neurofisiologia Clínica, Unitat d'Electromiografia (M.G., N.R.), and Servei de Neurologia (E.C.), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; and Division of Neurology (X.M.), University of Toronto, St Michael's Hospital, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000006251DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161544PMC
September 2018

Therapeutic Inertia in Multiple Sclerosis Care: A Study of Canadian Neurologists.

Front Neurol 2018 24;9:781. Epub 2018 Sep 24.

Division of Neurology, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fneur.2018.00781
Publisher Site
http://dx.doi.org/10.3389/fneur.2018.00781DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165907PMC
September 2018

Restoring Axonal Function with 4-Aminopyridine: Clinical Efficacy in Multiple Sclerosis and Beyond.

CNS Drugs 2018 07;32(7):637-651

Department of Neurology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40263-018-0536-2DOI Listing
July 2018

Usability of an Educational Intervention to Overcome Therapeutic Inertia in Multiple Sclerosis Care.

Front Neurol 2018 10;9:522. Epub 2018 Jul 10.

Healthcare Analytics Research, Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fneur.2018.00522DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048250PMC
July 2018

Multiple sclerosis, and other demyelinating and autoimmune inflammatory diseases of the central nervous system.

Handb Clin Neurol 2017 ;146:67-84

Neurology and Neuroimmunology Service, Multiple Sclerosis Center of Catalunya and Institut de Recerca Vall d'Hebron, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/B978-0-12-804279-3.00005-8DOI Listing
June 2018

Brain atrophy 15 years after CIS: Baseline and follow-up clinico-radiological correlations.

Mult Scler 2018 05 26;24(6):721-727. Epub 2017 Apr 26.

Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Edifici Cemcat, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1352458517707070DOI Listing
May 2018

Classic Block Design "Pseudo"-Resting-State fMRI Changes After a Neurorehabilitation Program in Patients with Multiple Sclerosis.

J Neuroimaging 2018 05 5;28(3):313-319. Epub 2018 Feb 5.

Section of Neuroradiology, Department of Radiology, University Hospital Vall d'Hebron, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jon.12500DOI Listing
May 2018

Ocrelizumab: a new milestone in multiple sclerosis therapy.

Ther Adv Neurol Disord 2018 10;11:1756286418773025. Epub 2018 May 10.

Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d'Hebron, Edif. Antiga EUI, Pl 2, Barcelona, 08035, SpainDivision of Neurology, University of Toronto, 190 Elizabet Street R. Fraser Elliott Building, 3-805, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1756286418773025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5952271PMC
May 2018

The value of oligoclonal bands in the multiple sclerosis diagnostic criteria.

Brain 2018 04;141(4):1075-1084

Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/brain/awy006DOI Listing
April 2018

Disease-modifying therapy in multiple sclerosis: Two guidelines (almost) passing in the night.

Mult Scler 2018 04;24(5):558-562

Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron University Hospital, Barcelona, Spain; Division of Neurology, University of Toronto, St Michael's Hospital, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1352458518767323
Publisher Site
http://dx.doi.org/10.1177/1352458518767323DOI Listing
April 2018

Disability progression markers over 6-12 years in interferon-β-treated multiple sclerosis patients.

Mult Scler 2018 03 13;24(3):322-330. Epub 2017 Mar 13.

Servicio de Neurologia-Neuroimmunolgia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1352458517698052
Publisher Site
http://dx.doi.org/10.1177/1352458517698052DOI Listing
March 2018

Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor.

Mult Scler 2018 03 16;24(3):301-312. Epub 2017 Mar 16.

Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1352458517697830
Publisher Site
http://dx.doi.org/10.1177/1352458517697830DOI Listing
March 2018

Varicella-zoster meningovasculitis in a multiple sclerosis patient treated with natalizumab.

Mult Scler 2018 03 23;24(3):358-360. Epub 2017 Jun 23.

Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d'Hebron, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1352458517711569DOI Listing
March 2018

Diagnosis of multiple sclerosis: a multicentre study to compare revised McDonald-2010 and Filippi-2010 criteria.

J Neurol Neurosurg Psychiatry 2018 03 19;89(3):316-318. Epub 2017 Jul 19.

Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jnnp-2017-315863DOI Listing
March 2018

Quantitative spinal cord MRI in radiologically isolated syndrome.

Neurol Neuroimmunol Neuroinflamm 2018 Mar 17;5(2):e436. Epub 2018 Jan 17.

Division of Neurology (P.A.-L., K.C., S.S., C.C., M.H., D.S., X.M., J.O.), Department of Medicine; Division of Neuroradiology (P.A.-L., G.L., A.B.), Department of Medical Imaging; Division of Neurosurgery (A.B.), Department of Surgery, St. Michael's Hospital, University of Toronto, Ontario, Canada; Department of Neurology-Neuroimmunology Neurorehabilitation Unit (X.M.), Multiple Sclerosis Center of Catalonia (Cemcat), Barcelona, Spain; and Department of Neurology (J.O.), Johns Hopkins University, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/NXI.0000000000000436DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5773843PMC
March 2018

Therapeutic Inertia in the New Landscape of Multiple Sclerosis Care.

Front Neurol 2018 20;9:174. Epub 2018 Mar 20.

Outcomes and Decision Neuroscience lab, Division of Neurology, Department of Medicine, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fneur.2018.00174DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5869922PMC
March 2018

Bone morphogenetic proteins in multiple sclerosis: Role in neuroinflammation.

Brain Behav Immun 2018 02 27;68:1-10. Epub 2017 Feb 27.

Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain; Universitat Autònoma de Barcelona, 08193 Bellaterra, Cerdanyola del Vallès, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbi.2017.02.019DOI Listing
February 2018

The optic nerve should be included as one of the typical CNS regions for establishing dissemination in space when diagnosing MS - No.

Mult Scler 2018 02 23;24(2):123-125. Epub 2017 Oct 23.

Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Department of Neurology/Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain/Division of Neurology, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1352458517729451DOI Listing
February 2018

Combined therapies to treat complex diseases: The role of the gut microbiota in multiple sclerosis.

Autoimmun Rev 2018 Feb 28;17(2):165-174. Epub 2017 Nov 28.

Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain; Universitat Autònoma de Barcelona, 08193, Bellaterra, Cerdanyola del Vallès, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autrev.2017.11.019DOI Listing
February 2018

Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study.

Lancet Neurol 2018 02 21;17(2):133-142. Epub 2017 Dec 21.

Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy; Department of Neurology, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1474-4422(17)30469-6DOI Listing
February 2018

ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.

Mult Scler 2018 02 20;24(2):96-120. Epub 2018 Jan 20.

Department of Neurology, Focus Program Translational Neuroscience (FTN) and Immunology (FZI), Rhine-Main Neuroscience Network (rmn2), University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1352458517751049DOI Listing
February 2018

Blood lymphocyte subsets identify optimal responders to IFN-beta in MS.

J Neurol 2018 Jan 12;265(1):24-31. Epub 2017 Oct 12.

Servicio de Inmunología, Hospital Universitario Ramón y Cajal, IRYCIS, Ctra. Colmenar km 9.100, 28034, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00415-017-8625-6DOI Listing
January 2018

Lesion topographies in multiple sclerosis diagnosis: A reappraisal.

Neurology 2017 Dec 3;89(23):2351-2356. Epub 2017 Nov 3.

From Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (CEMCAT) (G.A., M.T., J.R., J.C., A.V.-J., I.G., C.N., M.C., P.M., B.R.-A., L.M., J.S.-G., X.M.), and Magnetic Resonance Unit, Department of Radiology (IDI) (C.A., R.M., A.d.B., A.R.), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain; and Division of Neurology (X.M.), St. Michael's Hospital, University of Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000004715DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5719929PMC
December 2017

Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients.

Neurology 2017 Oct 15;89(15):1584-1593. Epub 2017 Sep 15.

From Biogen (T.P., K.K.M., G.K., D.M., K.E., M.S., I.N., Y.C., Q.D., P.-R.H., D.A.), Cambridge, MA; Ashfield Healthcare Communications (A.A.), Middletown, CT; Hôpital Civil (J.D.S.), Strasbourg, France; Mellen Center for Multiple Sclerosis (R.F.), Cleveland Clinic, OH; St. Josef Hospital (R.G.), Ruhr University, Bochum, Germany; Piedmont HealthCare (D.J.), Mooresville, NC; Neurologic Clinic and Policlinic (L.K.), Departments of Medicine, Clinical Research, Biomedicine, and Biomedical Engineering, University Hospital and University of Basel, Switzerland; Vall d'Hebron University Hospital (X.M.), Barcelona, Spain; Jacobs MS Center and Pediatric MS Center of Excellence (B.W.-G.), Jacobs Neurological Institute, Buffalo, NY; Department of Neurology (H.-P.H.), Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany; and University of California San Francisco Multiple Sclerosis Center (B.A.C.C.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000004485DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634662PMC
October 2017

Progressive MS trials: Lessons learned.

Mult Scler 2017 Oct;23(12):1583-1592

Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1352458517729460DOI Listing
October 2017

Semaphorin 7A as a Potential Therapeutic Target for Multiple Sclerosis.

Mol Neurobiol 2017 08 6;54(6):4820-4831. Epub 2016 Oct 6.

Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya, Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Ps. Vall d'Hebron, 119-129, 08035, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12035-016-0154-2DOI Listing
August 2017

Decreased soluble IFN-β receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker.

Mult Scler 2017 Jun 9;23(7):937-945. Epub 2016 Sep 9.

Unidad de Gestión Clínica de Neurociencias, Instituto de Biomedicina de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Universidad de Málaga, Málaga, Spain/Red Española de Esclerosis Múltiple (REEM).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1352458516667564DOI Listing
June 2017

Multiple Sclerosis: Epidemiologic, Clinical, and Therapeutic Aspects.

Neuroimaging Clin N Am 2017 May;27(2):195-204

Department of Neurology-Neuroimmunology, Multiple Sclerosis Centre of Catalonia, Edifici Cemcat, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Ps Vall d'Hebron 119-129, Barcelona 08035, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nic.2016.12.001DOI Listing
May 2017

Grey matter atrophy is associated with disability increase in natalizumab-treated patients.

Mult Scler 2017 Apr 11;23(4):556-566. Epub 2016 Jul 11.

Servei de Neurologia/Neuroimmunologia, Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1352458516656808DOI Listing
April 2017

Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis.

N Engl J Med 2017 04;376(17):1694

University of Texas Health Science Center at Houston, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1702076DOI Listing
April 2017

Metabolomic signatures associated with disease severity in multiple sclerosis.

Neurol Neuroimmunol Neuroinflamm 2017 Mar 27;4(2):e321. Epub 2017 Jan 27.

Center of Neuroimmunology (P.V., I.A., E.K., I.Z., I.P.-V., A.S.), Institute d'Investigaciones Biomediques August Pi Sunyer (IDIBAPS)-Hospital Clinic, Barcelona, Spain; University of California (P.V.), San Francisco; OWL (C.A., A.C.), Parque Tecnológico de Bizkaia, Derio; Cemcat (M.C., X.M.), Hospital Vall d'Hebron, Barcelona; Hospital Ramon y Cajal (L.V., J.C.A.-C.), Madrid; Hospital Universitario Regional (O.F.), Instituto de Investigación Biomédica (IBIMA), Malaga; and Hospital Clinico San Carlos (R.A.-L., R.A.), Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/NXI.0000000000000321DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5278923PMC
March 2017

Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis.

J Neuroimmunol 2017 02 18;303:62-65. Epub 2016 Dec 18.

Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01655728163031
Publisher Site
http://dx.doi.org/10.1016/j.jneuroim.2016.12.006DOI Listing
February 2017

Treatment decisions in multiple sclerosis - insights from real-world observational studies.

Nat Rev Neurol 2017 Feb 13;13(2):105-118. Epub 2017 Jan 13.

Department of Medicine, University of Melbourne, and Department of Neurology, Royal Melbourne Hospital, Grattan Street, Parkville, VIC 3050, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrneurol.2016.188DOI Listing
February 2017

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

N Engl J Med 2017 01 21;376(3):221-234. Epub 2016 Dec 21.

From the University of California, San Francisco (S.L.H.), and Genentech, South San Francisco (D.M., P.C., H.G.) - both in California; McGill University (A.B.-O., D.L.A.) and NeuroRx Research (D.L.A.), Montreal, and University of British Columbia, Vancouver, BC (A.T.) - both in Canada; University Vita-Salute San Raffaele, Milan (G.C.); Barts and the London School of Medicine and Dentistry, London (G.G.); Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf (H.-P.H.), and the Technical University of Munich and Munich Cluster for Systems Neurology, Munich (B.H.) - both in Germany; Icahn School of Medicine at Mount Sinai, New York (F.L.); Hospital Vall d'Hebron University, Barcelona (X.M.); University of Miami, Miami (K.W.R.); Medical University of Lodz and Center for Neurology, Lodz, Poland (K.S.); McGovern Medical School, University of Texas Health Science Center at Houston, Houston (J.S.W.); and F. Hoffmann-La Roche (G.K., P.F., S.B., N.M.) and University Hospital Basel, University of Basel (L.K.), Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1601277DOI Listing
January 2017

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.

N Engl J Med 2017 01 21;376(3):209-220. Epub 2016 Dec 21.

From Hospital Vall d'Hebron University, Barcelona (X.M.); University of California, San Francisco, San Francisco (S.L.H.), and Genentech, South San Francisco (D.M., H.G., P.C.) - both in California; University Hospital Basel, University of Basel (L.K.), and F. Hoffmann-La Roche (A.S., P.F., S.B., N.M.), Basel, Switzerland; McGill University (D.L.A., A.B.-O.) and NeuroRx Research (D.L.A.), Montreal, and University of British Columbia, Vancouver (A.T.) - both in Canada; University Vita-Salute San Raffaele, Milan (G.C.); University Hospital of Strasbourg, Clinical Investigation Center (INSERM Unité 1434), Fédération de Médecine Translationnelle de Strasbourg, Strasbourg, France (J.S.); Barts and the London School of Medicine and Dentistry, London (G.G.); Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf (H.-P.H.), and Technical University of Munich and Munich Cluster for Systems Neurology, Munich (B.H.) - both in Germany; Icahn School of Medicine at Mount Sinai, New York (F.L.); University of Miami, Miami (K.W.R.); Medical University of Łódź, Łódź, Poland (K.S.); and McGovern Medical School, University of Texas Health Science Center at Houston, Houston (J.S.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1606468DOI Listing
January 2017

Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop.

Mult Scler 2017 01 6:1352458516686847. Epub 2017 Jan 6.

Queen Square MS Centre, Department of Neuroinflammation, UCL Institute of Neurology, University College London, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1352458516686847DOI Listing
January 2017

Myeloid-derived suppressor cells expressing a self-antigen ameliorate experimental autoimmune encephalomyelitis.

Exp Neurol 2016 Dec 28;286:50-60. Epub 2016 Sep 28.

Gene and Cell Therapy Laboratory, Vall d'Hebron Institut de Recerca (VHIR), Passeig Vall d'Hebron 119-129, Barcelona 08035, Spain; Universitat Autònoma de Barcelona, 08193, Bellaterra, Cerdanyola del Vallès, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.expneurol.2016.09.012DOI Listing
December 2016

Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis.

Mult Scler Relat Disord 2016 Nov 3;10:204-212. Epub 2016 Nov 3.

Comprehensive Multiple Sclerosis Center, Thomas Jefferson University Hospital, 900 Walnut Street, Ste. 200, Philadelphia, PA 19107, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.msard.2016.10.010DOI Listing
November 2016

Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper.

Mult Scler 2016 10 19;22(11):1386-1396. Epub 2016 May 19.

Multiple Sclerosis Centre of Catalonia (Cemcat), Department of Neurology-Neuroimmunology, Vall d'Hebron University Hospital, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1352458516643600DOI Listing
October 2016

The 11-year long-term follow-up study from the randomized BENEFIT CIS trial.

Neurology 2016 Sep 10;87(10):978-87. Epub 2016 Aug 10.

From Neurology (L.K.), Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital Basel, Switzerland; CHU-Hopital Pontchaillou (G.E.), Rennes, France; University of Ottawa (M.S.F.), and the Ottawa Hospital Research Institute, Ottawa, Canada; Hospital Universitari Vall d'Hebron (X.M.), Ps. Vall d'Hebron, Barcelona, Spain; Department of Neurology (H.-P.H., R.S.), Medical Faculty, Heinrich-Heine Universität, Düsseldorf; Technische Universität München (B.H.), Munich, Germany; Central Texas Neurology Consultants (E.J.F.), Round Rock, TX; VU University Medical Center (F.B.), Amsterdam, the Netherlands; Neuroimmunology and Multiple Sclerosis Research (S.S.), Department of Neurology, University Hospital Zurich and University of Zurich, Switzerland; Bayer Pharma AG (A.S., C.P., E.-M.W.), Berlin; Myelo Therapeutics GmbH (D.P.), Berlin; University Hospital of Bonn (C.P.), Germany; and Bayer HealthCare Pharmaceuticals (G.S.), Whippany, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000003078DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5027814PMC
September 2016

Neurofilament light chain level is a weak risk factor for the development of MS.

Neurology 2016 Sep 12;87(11):1076-84. Epub 2016 Aug 12.

From Servei de Neurologia-Neuroimmunologia (G.A., C.E., H.E., J.S.-G., E.S., M.C., J.R., C.N., C.T., J.C., A.V.-J., I.G., M.J.A., X.M., M.T.), Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Vall d'Hebron Institut de Recerca, Hospital Universitari Vall d'Hebron, Barcelona; Universitat Autònoma de Barcelona (G.A., C.E., H.E., J.S.-G., E.S., M.C., J.R., C.N., C.T., J.C., A.V.-J., I.G., X.M., M.T.), Bellaterra; Departments of Neurology and Immunology (L.M.V., J.C.A.-C., C.P.), Multiple Sclerosis Unit, Hospital Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain; Department of Neurology (J.K., L.K.), University Hospital Basel; Neurocentre of Southern Switzerland (G.D.), Ospedale Civico, Lugano, Switzerland; and Magnetic Resonance Unit (IDI) (D.P., C.A., A.R.), Hospital Universitari Vall d'Hebron, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000003085DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5027802PMC
September 2016

Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis.

Neurology 2016 Sep 26;87(13):1368-74. Epub 2016 Aug 26.

From Centre d'Esclerosi Múltiple de Catalunya (CEMCAT), Department of Neurology/Neuroimmunology (M.T., S.O.-R., J.R., G.A., B.P., C.T., I.G., M.C., C.N., M.J.A., A.V.-J., J.C., B.R.-A., L.M., J.S.-G., X.M.), and Magnetic Resonance Unit, Department of Radiology (R.M., C.A., À.R.), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000003144DOI Listing
September 2016

Assessing response to interferon-β in a multicenter dataset of patients with MS.

Neurology 2016 Jul 15;87(2):134-40. Epub 2016 Jun 15.

From the University of Genoa (M.P.S.); Hospital San Camillo Forlanini (C.G.) and Department of Neurology and Psychiatry (L.P., C.P.), Sapienza University, Rome; Department of Neurology (M.R., V.M., G.C.) and Neuroimaging Research Unit (M.A.R., M.F.), San Raffaele Scientific Institute, Milan, Italy; Hospital Universitario Vall d'Hebron (J.R., M. Tintorè, A.R., X.M.), Barcelona, Spain; University of Verona (M.C.); Department of Public Health, Clinical and Molecular Medicine (E.C.), and Department of Medical Sciences (M.G.M., E.C.), University of Cagliari, Italy; Department of Neurology (C.E., F.F.), Medical University of Graz, Austria; Dip. to di Scienze Mediche, Chirurgiche, Neurologiche, Metaboliche e dell'Invecchiamento (A.G., G.T.), Seconda Universita' di Napoli, MRI Research Center "SUN-FISM," Hermitage-Capodimonte Clinic, Naples, Italy; Neurology (L.K., T.S.), Departments of Medicine, Clinical Research, and Biomedical Engineering, University Hospital Basel, Switzerland; DKD Helios Klinik Wiesbaden (T.S.), Germany; University of Siena (M.L.S., N.D.S.); and Department of Medical Sciences, Neurosciences and Sense Organs (M. Trojano, C.T.), University of Bari, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000002830DOI Listing
July 2016

Precision medicine in multiple sclerosis: biomarkers for diagnosis, prognosis, and treatment response.

Curr Opin Neurol 2016 06;29(3):254-62

Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/WCO.0000000000000336DOI Listing
June 2016

Novel Insights into the Multiple Sclerosis Risk Gene ANKRD55.

J Immunol 2016 06 4;196(11):4553-65. Epub 2016 May 4.

Neurogenomiks Laboratory, University of the Basque Country (University of Pais Vasco/Euskal Herriko University), 48170 Zamudio, Spain; Achucarro Basque Center for Neuroscience, 48170 Zamudio, Spain; IKERBASQUE, Basque Foundation for Science, 48013 Bilbao, Spain

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.1501205DOI Listing
June 2016